Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Karlqvist

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Therapeutic Advances in Gastroenterology|July 28, 2025
Healthcare resource utilization and production loss in vedolizumab-treated inflammatory bowel disease patients: results from the Swedish prospective multicentre SVEAH studyLinda Ryen, Isabella Visuri, Sara Karlqvist, et al.
The American Journal of Gastroenterology|July 12, 2024
Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish RegistersSara Karlqvist, Michael C Sachs, Carl Eriksson, et al.
The American Journal of Gastroenterology|December 24, 2024
Response to Dai et alSara Karlqvist, Michael C Sachs, Carl Eriksson, et al.
Digestive Diseases and Sciences|March 17, 2023
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's DiseaseCarl Eriksson, Jonas Söderling, Sara Karlqvist, et al.
Therapeutic Advances in Gastroenterology|June 5, 2023
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension studyIsabella Visuri, Carl Eriksson, Sara Karlqvist, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Therapeutic Advances in Gastroenterology|July 28, 2025
Healthcare resource utilization and production loss in vedolizumab-treated inflammatory bowel disease patients: results from the Swedish prospective multicentre SVEAH studyLinda Ryen, Isabella Visuri, Sara Karlqvist, et al.
The American Journal of Gastroenterology|July 12, 2024
Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish RegistersSara Karlqvist, Michael C Sachs, Carl Eriksson, et al.
The American Journal of Gastroenterology|December 24, 2024
Response to Dai et alSara Karlqvist, Michael C Sachs, Carl Eriksson, et al.
Digestive Diseases and Sciences|March 17, 2023
Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's DiseaseCarl Eriksson, Jonas Söderling, Sara Karlqvist, et al.
Therapeutic Advances in Gastroenterology|June 5, 2023
Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension studyIsabella Visuri, Carl Eriksson, Sara Karlqvist, et al.
Pageof 1